R&D channel feed

Down but not out: FDA re­jects Proven­tion's di­a­betes drug as com­mer­cial prod­uct dif­fers from tri­al drug

4 years ago
FDA+

The CRO mad­ness con­tin­ues as Gold­man Sachs-backed buy­er group shells out $8.5B for Parex­el

4 years ago
Deals

Duke to host pri­vate meet­ing with pay­ers and bio­phar­ma on how to pay for Alzheimer's drugs

4 years ago
Pharma
FDA+

A gene ther­a­py to re­store dam­aged tis­sue af­ter a heart at­tack clears pigs

4 years ago

Ar­row­head rocked by an­i­mal tox is­sues again, hit­ting the pause but­ton on RNAi study in cys­tic fi­bro­sis

4 years ago

The class of mol­e­cules be­hind one of biotech's biggest Alzheimer's fail­ures gets a new lease on life

4 years ago
Deals

Evotec ex­pands pres­ence in Italy with ac­qui­si­tion of for­mer Glax­o­SmithK­line R&D site

4 years ago
Outsourcing

Mer­ck to with­draw dan­gling ac­cel­er­at­ed ap­proval for Keytru­da in third-line stom­ach can­cer

4 years ago
FDA+

New to the par­ty, No­var­tis seeks to plunge in­to mR­NA

4 years ago

Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed field

4 years ago
Financing

Roche mulling quick fil­ing for a tar­nished Alzheimer’s drug as con­tro­ver­sial Aduhelm OK elec­tri­fies the field — an­a­lyst

4 years ago
FDA+

Roche reach­es out once again for the bud­get ax with plans to chop up to 400 de­vel­op­ment jobs in R&D

4 years ago
Pharma

Catal­ent bags a Ger­man stem cell de­vel­op­er to build its next-gen ther­a­peu­tics wing

4 years ago
Outsourcing
Manufacturing

Pfiz­er bets on Spero can­di­date, wad­ing deep­er along­side GSK and Roche in­to aban­doned an­tibi­ot­ic mar­ket

4 years ago

An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

4 years ago
Coronavirus

Joe Jimenez and Mark Fish­man sign up their 5th drug can­di­date — and they have an­oth­er big tar­get in their crosshairs

4 years ago
Deals

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

4 years ago
Cell/Gene Tx

Ab­b­Vie says Rin­voq shines again as main­te­nance ther­a­py for ul­cer­a­tive col­i­tis — but safe­ty con­cerns still loom over JAK class

4 years ago
Pharma

Is 9 years too long to run a con­fir­ma­to­ry study for a drug like ad­u­canum­ab? In Sarep­ta’s case, it isn’t enough time

4 years ago
Bioregnum

Cerev­el's stock rock­ets up on re­lease of ear­ly da­ta in schiz­o­phre­nia, fol­lowed by an of­fer­ing

4 years ago

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

4 years ago
Coronavirus

'Bi­ased and mis­lead­ing': No holds barred in FDA's sta­tis­ti­cal re­view of Bio­gen's Aduhelm

4 years ago
FDA+

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

4 years ago
Cell/Gene Tx
Manufacturing

Con­tro­ver­sial an­ti-ag­ing sci­en­tist — backed by Har­vard's George Church — makes a fresh round of claims on life ex­ten­sion in new mouse study

4 years ago
Discovery
First page Previous page 165166167168169170171 Next page Last page
A service from the Financial Times